Hatch Waxman act Archives - World School of Life Sciences IP

Eliquis to face generic competition in late 2026?

Tanu Goyal October 30, 2023

Eliquis to face generic competition in late 2026? Bristol Myers Squibb (BMS) and Pfizer’s oral blood thinner – Eliquis® (Apixaban) was approved in the United

Generics for Otezla® to be out in the United States in February 2028

Tanu Goyal September 14, 2023

Generics for Otezla® to be out in the United States in February 2028 Amgen’s oral phosphodiesterase-4 (PDE-4) inhibitor – Otezla® (Apremilast) is approved in the

Preventing Delays in Generic Drug Entry

Tanu Goyal August 24, 2023

Preventing Delays in Generic Drug Entry Generic drugs are identical to their brand-name counterparts in safety, effectiveness, strength, and quality. Also, they offer the same therapeutic

WSLI

Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.